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Chemotherapies for brain diseases have been hampered due to the inability of transport of drug across the blood-brain barrier 
(BBB). In order to overcome the barrier, p-hydroxybenzoic acid (p-HA), a small molecule of benzamide analogue, was used as a 
ligand for brain-targeted drug delivery. The p-HA was conjugated to PEG-DSPE to form p-HA-PEG-DSPE. Docetaxel-loaded 
polymeric micelles were prepared by a thin-film hydration method using methoxy-poly(ethylene glycol)-distearoylphosphatidyl- 
ethanolamine (mPEG2000-DSPE) as a carrier and the p-HA-PEG-DSPE as a brain targeted material. The prepared micelles showed 
spherical with a mean diameter of (18±3) nm. Encapsulation efficiency and drug loading were (83.49±1.3)%, (7.7±1.2)% for un-
modified micelles and (80.65±1.6)%, (7.47±1.8)% for p-HA-modified micelles, respectively. In vitro cellular uptake experiments 
showed that the p-HA-modified micelles increased BCECs cellular uptake by 1.2 times compared to the unmodified micelles. Ex 
vivo near-infrared fluorescence imaging showed that brain uptake of the p-HA-modified micelles was 1.3–1.8 times higher than 
that of the unmodified micelles. In vitro cytotoxicity assay against glioblastoma cell U87 MG showed that inhibition rate of the 
p-HA-modified micelles increased by 1.2 times compared to that of the unmodified micelles and 1.7 times compared to that of 
DTX. Survival time of nude mice bearing intracranial glioblastoma showed that the lifetime of saline group, Taxotere group, 
mPEG-DSPE/DTX micelles group and p-HA-PEG-DSPE/DTX micelles group was 22, 27, 32 and 45.8 d, representively, which 
indicated that anti-glioblastoma activity of DTX could be significantly enhanced by the p-HA-modified polymeric micelles. These 
results demonstrated that the p-HA-modified micelles could be a promising brain-targeted drug delivery system for hydrophobic 
drugs against glioblastoma. 
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Blood-brain barrier (BBB) is a physical dynamic barrier 
between brain and blood, which serves as a protection bar-
rier to effectively prevent certain foreign substances from 
entering the brain blood circulation. Due to poor permeabil-
ity of the BBB, nearly 100% of large molecules and 98% of 
small molecules are forbidden access to central nervous 
system (CNS). Consequently, it hampers treatment and di-
agnosis of CNS diseases such as Alzheimer’s diseases, 
brain tumors, and Parkinson’s diseases [1–4].  
To deliver therapeutic agents across the BBB, mecha-
nisms for transport of endogenous molecules into the brain 
have been employed such as receptor-mediated endocytosis, 
adsorptive mediated transcytosis, transporter uptake and 
membrane permeation of lipophilic molecules [5,6]. Re-
ceptor-mediated drug delivery systems represent very 
promising non-invasive strategy for active targeted drug 
delivery to the site of brain tumors [7–9]. Various receptors 
and transporters are present on the luminal endothelial 
plasma membranes, including the transferrin receptor [10], 
the insulin receptor [11], endothelial growth factor receptor 
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[12], low-density lipoprotein receptor [13] and glucose 
transporter [14] providing binding targets for drug delivery 
systems. 
Benzamide analogue is a kind of small molecules used 
for the treatment of central nervous diseases. Among them, 
tiapride could be used for the treatment of behavioral dis-
turbances and non-cognitive symptoms in children agitation; 
sultopride has strong antipsychotic effects [15,16]. Ben-
zamide analogues were found to have high affinity with 
dopamine receptors that are prominent in most parts of CNS. 
D1 and D2 dopamine receptors could be found in nigrostri-
atal pathway comprising the neurons of the substantia nigra 
and neostriatum [17]. In recent years, a considerable amount 
of research has been directed towards synthesis of substi-
tuted benzamides as ligands for visualization of dopamine 
D2 receptor binding in the brain by positron emission to-
mography [18]. 
Of the nanopartical drug delivery systems, PEG-lipid 
micelles have been extensively used as vehicles for hydro-
phobic drugs due to the high stability, controlled drug re-
lease, and low toxicity [19–24]. In the present study, a novel 
brain-targeted nanoparticle drug delivery system based on a 
small molecule ligand (p-Hydroxybenzoic Acid, p-HA) was 
developed [25]. Few studies have reported on PEG-DSPE 
micelles modified with p-HA. In this study, p-HA-modified 
micelles was first established, then in vitro and in vivo tar-
geting effect of the micelles was investigated. The an-
ti-gliobalstoma efficacy of DTX-loaded micelles was stud-
ied on intracranial glioblastoma bearing nude mice.  
1  Materials and methods 
1.1  Materials 
DIEA (Diisopropylethylamine) were supplied by Fluka 
(Milwaukee, USA). Docetaxel was kindly provided by Prof. 
Y. P. Li from Shanghai Institute of Materia Medica (SIMM). 
EDC·HCl (1-Ethyl-3-(3-dimethyllaminopropyl) carbodii- 
mide hydrochloride) were purchased from GL Biochem Ltd 
(Shanghai, China). mPEG2000-DSPE (methoxy-poly(eth- 
ylene glycol)-distearoylphosphatidylethanolamine) was pur-
chased from Lipoid GmbH (Ludwigshafen, Germany). NH2- 
PEG-DSPE was purchased from Laysan Bio Co. (USA). 
DiR (1,1′-dioctadecyl-3,3,3′,3′tetramethyl indotricarbocya-
nine iodide) was from Invitrogen (USA). DMEM medium 
and FBS (fetal bovine serum) were purchased from Gibco 
Co. (USA). Methanol, acetonitrile, and other HPLC grade 
reagents were obtained from Fisher Scientific (USA). All 
the chemicals were analytic reagent grade. 
1.2  Cell lines and animals 
Brain capillary endothelial cells (BCECs) were kindly pro-
vided by Prof. X. G. Jiang (School of Pharmacy, Fudan 
University). U87 MG cell line was obtained from the Insti-
tute of Biochemistry and Cell Biology, Shanghai Institute 
for Biological Sciences, Chinese Academy of Sciences. 
Both cells were cultured in DMEM medium, supplemented 
with 10% FBS, 100 IU/mL penicillin and 100 mg/mL strep-
tomycin sulfate. All the cells were cultured in incubators 
maintained at 37°C with 5% CO2 under fully humidified 
conditions. All the experiments were performed on cells 
(passages from 5 to 30) in the logarithmic phase of growth. 
BALB/c nude mice (male, 4–5 weeks, weighing 18–20 g) 
were supplied by Department of Experimental Animals, 
Fudan University (Shanghai, China). All the animal exper-
iments were carried out in accordance with guidelines eval-
uated and approved by the Ethics Committee of Fudan 
University. 
1.3  Synthesis and characterization of p-HA-PEG- 
DSPE 
p-HA (27.6 mg) was dissolved in anhydrous DMF (3 mL) 
together with NHS and EDC·HCl. Then 20 μL of DIEA 
were added and incubated for 3 h. The resulting mixture 
was centrifuged and the supernatant was added dropwise 
into a solution of NH2-PEG-DSPE in anhydrous DMF (72 
mg/mL). The solution was stirred overnight at room tem-
perature and precipitated using cold diethyl ether for three 
times. The precipitation was then vacuum-dried for 2 h. The 
resulting p-HA-PEG-DSPE was purified using a dialysis 
method (MWCO 3.5 kD, Millipore) against distilled water. 
Finally the p-HA-PEG-DSPE solution was lyophilized and 
stored at −20°C. The structure of the conjugates was char-
acterized via 1H-NMR spectroscopy using CDCl3 as a sol-
vent at 25°C. 
1.4  Preparation and characterization of p-HA-PEG- 
DSPE micelles 
(1) Preparation of micelles. Micelles loaded with coumarin 
6, DiR or DTX were prepared using the thin-film hydration 
and extrusion method [26]. A mixture of mPEG-DSPE/p- 
HA-PEG-DSPE (95:5 by molar) with coumarin 6, DiR or 
DTX in acetonitrile was rotary evaporated to form a thin 
film. Then the film was vacuum desiccated overnight. To 
form spontaneous self-assembly of the micelles, the dried 
polymeric film was dissolved in 10 mmol/L HEPES-buff- 
ered saline (HBS, pH 7.4) and incubated at a constant tem-
perature of 37°C under stirring for 0.5 h. The obtained mi-
celle was filtrated against 0.22 μm filter membrane (milli-
pore) to remove unencapsulated DTX. To purify the cou-
marin 6 and DiR-loaded micelles, size exclusive chroma-
tography was carried on a G-50 gel column using HBS as 
the mobile phase.  
The particle size and distribution were determined via 
dynamic light scattering (DLS) analysis using Malvern 
Zetasizer Nano ZS (Malvern, UK) at 25°C. Each test was 
measured in triplicate. The morphology of the micelles was 
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studied using Transmission Electron Microscope (TEM). 
(2) Drug-loading capacity, encapsulation efficiency and 
in vitro release. To value the encapsulation efficiency (E.E.) 
and loading capacity (L.C.), the DTX-loaded micelle was 
diluted in acetonitrile and the concentration of DTX was 
measured via HPLC (mobile phase: acetonitrile/water 
(65/35, v/v), λ: 230 nm) [27]. E.E. was defined as the ratio 
between actual DTX amount determined and theoretic 
feeding DTX amount. L.C. was defined as the ratio between 
DTX amount determined and the weight of lyophilized mi-
celles. 
In vitro release profiles of the DTX-loaded micelles were 
performed in 20 mL of PBS containing 0.5% of Tween-80. 
Release samples analyzed via HPLC. 
1.5  Targeting ability study of p-HA-PEG-DSPE  
micelles 
(1) Cellular uptake of p-HA-PEG-DSPE micelles.  Cellular 
internalization of coumarin 6-loaded micelles were studied. 
BCECs cells were seeded into 12-well plates, and each mi-
celle formulation with the same coumarin 6 concentration of 
25 ng/mL was added and incubated at 37°C for 1 h. After 
incubation, the medium was removed and the cells were 
washed three times with PBS, then visualized using a fluo-
rescent microscope. For quantitative analysis, BCECs cells 
were trypsinized and centrifuged (1000 r/min, 5 min), 
washed, resuspended in PBS and analyzed using a flow cy-
tometer (FACSAria, BD, USA). 
(2) In vivo distribution of p-HA-PEG-DSPE micelles. 
Potential brain-targeting effect of p-HA-PEG-DSPE mi-
celles was evaluated in normal nude mice [25]. Following 
i.v. administration, time-dependent biodistribution of the 
DiR-labeled micelles was observed at 1, 2, 4, 8, 12 and 24 h, 
respectively. The mice were then sacrificed to excise major 
organs that were photographed ex vivo. 
1.6  Pharmacodynamic study of p-HA-PEG-DSPE  
micelles 
(1) In vitro cytotoxicity assay.  In vitro cytotoxicity was 
determined using the MTT assay [28]. U87 MG cells were 
seeded to 96-well plates in 200 μL of medium to obtain a 
concentration of 3×103 cells per well, and then the plates 
were incubated for 24 h. The medium in each well was re-
freshed with 200 μL of the p-HA-PEG-DSPE/DTX micelles, 
mPEG-PEG-DSPE/DTX micelles and Taxotere® respec-
tively and incubated at 37°C for 72 h. The concentration of 
DTX ranged from 0.625 to 102.4 μmol/L. Experiments were 
repeated for at least three times. Percent cell viability was 
calculated on the basis of optical density values of sample 
wells versus reference wells (PowerWave XS, Bio-TEK, 
USA). 
(2) Anti-glioblastoma study of p-HA-PEG-DSPE/DTX 
micelles.  Therapeutic efficacy of DTX-loaded micelles 
was investigated in a xenograft mouse model bearing hu-
man U87 multiforme glioblastoma [29]. The intracranial 
U87MG bearing nude mice were randomly divided into four 
groups (n=9) and treated with the p-HA-PEG-DSPE/DTX 
micelles, unmodified mPEG-PEG-DSPE/DTX micelles, 
Taxotere® and saline (dose: 8 mg/ kg of body weight at 6, 9, 
12, and 15 d post-tumor implantation). The survival times 
were recorded. 
2  Result and discussion 
2.1  Characterization of p-HA-PEG-DSPE 
The conjugation of p-HA to PEG-DSPE was confirmed 
from the 1H-NMR spectrum. Results showed that the pro-
tons of p-HA at 6.8–7.8 ppm. The chemical shifts at 3.2–4.0 
ppm and 0.8–1.5 represent the PEG (–O–CH2–CH2–O–) and 
the DSPE, respectively. The 1H-NMR spectrum results in-
dicated the successful synthesis of p-HA-PEG-DSPE. 
2.2  Characterization of the p-HA-PEG-DSPE micelles 
As shown in Figure 1, the p-HA-PEG-DSPE/DTX micelles, 
the mPEG-DSPE/DTX micelles and blank micelles showed 
spherical morphology with mean diameters around 18 nm. 
The micelles with or without p-HA modification showed 
similar particle sizes, polydispersity indexes as well as drug 
leakage rates, which indicated that the incorporation of 
p-HA-PEG-DSPE into micelles had no influence on the 
physical properties of the PEG-DSPE micelle system. 
Encapsulation efficiency and drug loading were (83.49±  
 
 
Figure 1  Transmission electron microscope photographs of the micelles (×80000). (a) mPEG-PEG-DSPE/DTX micelles; (b) p-HA-PEG-DSPE/DTX 
micelles; (c) mPEG-PEG-DSPE micelles (blank). 
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1.3)%, (7.7±1.2)% for unmodified micelles and (80.65± 
1.6)%, (7.47±1.8)% for p-HA-modified micelles, respec-
tively. 
Drug leakage rates at pH 7.4 and pH 5.0 in 96 h are 
shown in Figure 2. Both of the p-HA-PEG-DSPE/DTX mi-
celles and mPEG-PEG-DSPE/DTX micelles exhibited a 
sustained-release profile in that the total DTX release from 
micelles was about 40% in the initial 24 h in PBS (pH 7.4), 
50% in PBS (pH 7.4) and 74% in PBS (pH 5.0) for 96 h, 
respectively (Figure 2(a)). At the same time, there was no 
obvious difference between p-HA-DTX micelle and mPEG- 
DTX micelle (Figure 2(b)). 
2.3  Targeting ability study of p-HA-PEG-DSPE  
micelles 
(1) Cellular uptake of the p-HA-PEG-DSPE micelles.  In 
vitro cellular uptake was qualitatively determined by fluo-
rescent images and quantitatively as a percentage of couma-
rin 6 positive cells (Figure 3). As shown in Figure 3, p-HA- 
PEG-DSPE/C6 micelles were internalized by BCECs cells 
more efficiently than mPEG-PEG-DSPE/C6 micelles. Flow 
cytometry experiments showed the percentage of coumarin 
6-positive cells increased from 72.4% to 92.9%, and mean 
fluorescence intensity increased from 7.5 to 14.8. All these  
 
 
Figure 2   In vitro drug release profiles of DTX-loaded micelles in pH 5.0 and 7.4 PBS at 37°C (a) (n=3, mean±SD); in vitro drug release profiles of 
DTX-loaded micelles from 7.4 PBS at 37°C (b) (n=3, mean±SD). 
 
Figure 3  Cellular internalization of free C6 and the C6-loaded micelles. Panels above: micrographs taken in the phase-contrast mode, panels below: the 
same field viewed in the fluorescence mode. (a)–(c) Free C6; (d)–(f) mPEG-PEG-DSPE/C6; (g)–(i) p-HA-PEG-DSPE/C6. 
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results indicated that p-HA could enhance micelles uptake 
by BCECs cells in vitro. 
(2) In vivo distribution of p-HA-PEG-DSPE/DiR mi-
celles. p-HA-PEG-DSPE/DiR micelles and mPEG-DSPE/ 
DiR micelles were injected via caudal vein in normal nude 
mice. Visible fluorescence accumulation appeared much 
stronger in the brains of p-HA-PEG-DSPE/DiR micelle 
group, compared with the normal micelle group through the 
entire studies (Figure 4). Ex vivo fluorescent image and 
semi quantitative of excised organs further confirmed that 
fluorescence accumulation in the brains treated with the 
p-HA-PEG-DSPE/DiR micelles were 1.3–1.8 times higher 
compared with the normal micelle group, except for the 
highest fluorescence in liver which had high macrophage 
uptake nature. Compared with the normal micelle group, 
fluorescence signal in the brains of the p-HA-PEG-DSPE 
micelle group was remarkably stronger at any time 
post-injection ranged from 2 to 12 h (Figure 5). 
(3) In vitro cytotoxicity studies.  In vitro cytotoxicity of 
DTX-loaded micelles was evaluated on U87 MG cells via 
MTT assay. Growth inhibition effect against U87 MG cells 
was observed in both groups. The IC50 values for Taxotere, 
the mPEG-DSPE/DTX micelles and the p-HA-PEG-DSPE/ 
DTX micelles were 177.8, 125.9, and 104.7 nmol/L, respec-
tively. The IC50 of the DTX-loaded micelles were lower 
than Taxotere®, indicating that the micelles were more effi-
cient to mediate the cytotoxic effect of DTX than Taxotere  
 
Figure 4  In vivo non-invasive NIR fluorescence images of the p-HA- 
PEG-DSPE/DiR (rats at the right side) and the mPEG-DSPE/DiR (rats at 
the left side) after intravenous administration. 
to U87 MG tumor cells. 
(4) Anti-glioblastoma studies of the p-HA-PEG-DSPE/ 
DTX micelles.  Figure 6 represents Kaplan-Meier survival 
curves of the DTX-loaded formulations. The median sur-





Figure 5  Ex vivo imaging and semi-quantitative analysis of dissected organs at different time points. (A) mPEG-DSPE/DiR micelles; (B) p-HA-PEG- 
DSPE/DiR micelles. 
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Figure 6  Kaplan-Meier survival curves of mice bearing intracranial U87 
glioblastoma. 
mPEG-DSPE/DTX micelle group, Taxotere® group and 
saline group were 45.8, 32, 27 and 22 d, repretively. These 
results demonstrated that the survival of the p-HA-PEG- 
DSPE/DTX micelle group was significantly longer than 
those of other groups (P<0.05). These survival data sug-
gested that p-HA could mediate BBB transport of polymeric 
micelles, thus enhancing therapeutic efficacy of chemo-
therapy drugs against brain tumors. 
3  Conclusions 
The p-HA-modified micelles exhibited strong enhancement 
on the uptake against the BBB both in vitro and in vivo. All 
data indicated that this novel small molecular (p-HA) can be 
used in the anti-tumor drug delivery system which targeting 
to the brain, and, p-HA-conjuncted micelles could have a 
potential value of clinical application. 
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